Indegene (www.indegene.com), a leading global pharmaceutical and healthcare solutions provider, today announced a new release of TrialPedia 2.0, its flagship clinical trial analytics and benchmarking platform. This enhanced version has analytics and benchmarking algorithms spanning over 200,000 trials across 200 indications, making it the most comprehensive and effective clinical trial analysis platform in the marketplace.
Today's Research and Development (R&D), Clinical, Medical Affairs, Health Outcomes, and Business Development and Licensing divisions face dramatic challenges in designing trial programs, formulating clinical development strategies, and forecasting the future 'claim space' in order to benchmark and maximize the value of their pipeline. Operational challenges as well as, time and cost delays in clinical trials can have a significant impact on revenues and future profitability. TrialPedia 2.0 further enhances the quality, speed, and effectiveness of the clinical development and strategic planning process for global pharmaceutical, device, and biotech organizations. This new release includes improved granular search, advanced sub-disease classification, expanded trial and indication coverage, increased geographical scope, and disease-specific interventions.
The platform makes the identification of gaps, and development of appropriate benchmarks for the clinical development process more efficient. This is particularly important, given the increase in regulatory thresholds and challenges surrounding adverse events. It helps minimize this by identifying industry best practices vis-à-vis safety and efficacy, thereby avoiding costly late-stage delays and failures. The new release marks advanced analytics and benchmarking tools to provide for an aggressive strategy of label leadership across sub-indications, biomarkers, and launch preparations.
About Indegene
Indegene is a leading provider of R&D, commercial and marketing solutions to global pharmaceutical and healthcare organizations. We partner with clients to drive both productivity and revenues by delivering better patient outcomes; optimizing cost; enhancing R&D agility and improving sales and marketing effectiveness. We apply deep scientific knowledge, flexible delivery models, proprietary technology, and a client-centric approach to drive transformational initiatives.
With offices in US, UK, China, India, and Australia, Indegene can partner globally with clients, leverage a global talent pool of clinicians, technologists, creative specialists, domain experts, business process specialists, deploy global infrastructure assets, and harness global healthcare knowledge to solve client challenges. To learn more about Indegene, visit us at www.indegene.com.
Today's Research and Development (R&D), Clinical, Medical Affairs, Health Outcomes, and Business Development and Licensing divisions face dramatic challenges in designing trial programs, formulating clinical development strategies, and forecasting the future 'claim space' in order to benchmark and maximize the value of their pipeline. Operational challenges as well as, time and cost delays in clinical trials can have a significant impact on revenues and future profitability. TrialPedia 2.0 further enhances the quality, speed, and effectiveness of the clinical development and strategic planning process for global pharmaceutical, device, and biotech organizations. This new release includes improved granular search, advanced sub-disease classification, expanded trial and indication coverage, increased geographical scope, and disease-specific interventions.
The platform makes the identification of gaps, and development of appropriate benchmarks for the clinical development process more efficient. This is particularly important, given the increase in regulatory thresholds and challenges surrounding adverse events. It helps minimize this by identifying industry best practices vis-à-vis safety and efficacy, thereby avoiding costly late-stage delays and failures. The new release marks advanced analytics and benchmarking tools to provide for an aggressive strategy of label leadership across sub-indications, biomarkers, and launch preparations.
About Indegene
Indegene is a leading provider of R&D, commercial and marketing solutions to global pharmaceutical and healthcare organizations. We partner with clients to drive both productivity and revenues by delivering better patient outcomes; optimizing cost; enhancing R&D agility and improving sales and marketing effectiveness. We apply deep scientific knowledge, flexible delivery models, proprietary technology, and a client-centric approach to drive transformational initiatives.
With offices in US, UK, China, India, and Australia, Indegene can partner globally with clients, leverage a global talent pool of clinicians, technologists, creative specialists, domain experts, business process specialists, deploy global infrastructure assets, and harness global healthcare knowledge to solve client challenges. To learn more about Indegene, visit us at www.indegene.com.
